培美曲塞联合奈达铂治疗晚期肺腺癌的临床观察 |
| |
引用本文: | 顾胤,魏荣富,李双根,胡骏. 培美曲塞联合奈达铂治疗晚期肺腺癌的临床观察[J]. 医学理论与实践, 2013, 0(21): 2809-2810,2822 |
| |
作者姓名: | 顾胤 魏荣富 李双根 胡骏 |
| |
作者单位: | 江苏省高淳县人民医院肿瘤科,211300 |
| |
摘 要: | 目的:评价培美曲塞联合奈达铂治疗晚期肺腺癌的疗效及不良反应。方法:入组32例经病理确诊的晚期肺腺癌患者,给予培美曲塞500mg/m^2静滴,第1天;奈达铂80mg/m2静滴,第1天,3周为1个周期,2个周期后评价疗效及不良反应。结果:32例患者中完全缓解(CR)0例,部分缓解(PR)9例,稳定(SD)15例,进展(PD)8例。有效率 RR (CR+ PR)28.1%。中位生存期11.8个月,1年存活率46.9%。结论:培美曲塞联合奈达铂治疗晚期肺腺癌具有较好的疗效及安全性。
|
关 键 词: | 培美曲塞 奈达铂 肺腺癌 化学治疗 |
Clinical Observation of Pemetrexed Combined Nedaplat in the Treatment of Patients with Advanced Lung Adenocarcinoma |
| |
Affiliation: | GU Yin, WEI Rongfu, LI Shuanggen, et al. Department of Medical Oncology , People's Hospital of Gaochun County, J iangsu Province 211300 |
| |
Abstract: | Objective:To observe the therapeutic effect and toxicity of Pemetrexed combined Nedaplat in the treatment of patients with advanced lung adenocarcinoma. Methods: The 32 patients with pathologically confirmed lung adenocar- cinoma were treated with Pemetrexed 500mg/m^2 and Nedaplat 80mg/m^2 , dl, ivdrip, the schedule was repeated every 3 weeks and were evaluated effect after 2 cycles. Results: No patients had complete response(CR), 9 patients had partial response(PR), 15 patients had SD, 8 patients had PD, RR(CR+PR)28. 1 % (9/32). The median survival time was 11.8 months. The 1-year survival rate was 46. 9 %. Condusion:The pemetrexed combined nedaplat is effective and safe in the treatment of advanced lung adenocarcinoma patients. |
| |
Keywords: | Pemetrexed Nedaplat Lung ad Chemotherapy |
本文献已被 维普 等数据库收录! |
|